全文获取类型
收费全文 | 3052篇 |
免费 | 344篇 |
国内免费 | 63篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 48篇 |
妇产科学 | 27篇 |
基础医学 | 266篇 |
口腔科学 | 67篇 |
临床医学 | 245篇 |
内科学 | 273篇 |
皮肤病学 | 21篇 |
神经病学 | 213篇 |
特种医学 | 168篇 |
外科学 | 220篇 |
综合类 | 314篇 |
预防医学 | 1010篇 |
眼科学 | 51篇 |
药学 | 259篇 |
3篇 | |
中国医学 | 124篇 |
肿瘤学 | 95篇 |
出版年
2024年 | 3篇 |
2023年 | 62篇 |
2022年 | 90篇 |
2021年 | 150篇 |
2020年 | 186篇 |
2019年 | 159篇 |
2018年 | 121篇 |
2017年 | 138篇 |
2016年 | 103篇 |
2015年 | 121篇 |
2014年 | 224篇 |
2013年 | 250篇 |
2012年 | 202篇 |
2011年 | 204篇 |
2010年 | 163篇 |
2009年 | 144篇 |
2008年 | 120篇 |
2007年 | 117篇 |
2006年 | 106篇 |
2005年 | 100篇 |
2004年 | 88篇 |
2003年 | 73篇 |
2002年 | 65篇 |
2001年 | 52篇 |
2000年 | 46篇 |
1999年 | 21篇 |
1998年 | 41篇 |
1997年 | 36篇 |
1996年 | 39篇 |
1995年 | 17篇 |
1994年 | 15篇 |
1993年 | 16篇 |
1992年 | 21篇 |
1991年 | 27篇 |
1990年 | 16篇 |
1989年 | 13篇 |
1988年 | 12篇 |
1987年 | 8篇 |
1986年 | 13篇 |
1985年 | 10篇 |
1984年 | 13篇 |
1983年 | 8篇 |
1982年 | 9篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1979年 | 7篇 |
1977年 | 6篇 |
1976年 | 4篇 |
1975年 | 2篇 |
1973年 | 2篇 |
排序方式: 共有3459条查询结果,搜索用时 156 毫秒
61.
目的分析目前公布的国医大师预防或治疗新型冠状病毒肺炎(COVID-19)的处方,解读其辨证思路及用药规律。方法检索国医大师公布的关于预防或治疗COVID-19的处方,检索期限自2020年1月1日至2020年2月12日。结果共9位国医大师公布了22个处方。周仲瑛、孙光荣、唐祖宣、李佃贵、金世元、王琦、熊继柏、刘祖贻共8位国医大师开具了9个预防用方,涉及中药32味,处方以益气、化湿、清热解毒为主,辅以养阴清热、疏风解表、宣肺化痰。唐祖宣、杨春波、李佃贵、孙光荣4位国医大师开具了10个治疗类处方,涉及中药61味,处方以化湿、清热、解毒为基本法则,唐老按湿邪与寒、热、毒邪分型证治,杨老依湿邪在体内的传变为辨证依据,李老专攻"湿热浊毒",孙老强调"疏风清热"。李佃贵、周仲瑛、王琦3位国医大师开具了3个香囊处方,涉及中药14味,均选用了藿香芳香化湿。结论多位国医大师积极参与防治COVID-19,对本病的病因病机认识基本一致,不论是治疗处方或是预防处方皆以益气、化湿、清热、解毒为主,结合用药频次统计,使用药物最多的是黄芪、藿香、金银花,具体证治方面则不尽相同。 相似文献
62.
《Vaccine》2022,40(2):196-205
BackgroundHepatitis A virus (HAV) is a global health concern as outbreaks continue to occur. Since 1999, several countries have introduced universal vaccination (UV) of children against HAV according to approved two-dose schedules. Other countries have implemented one-dose UV programs since 2005; the long-term impact of this schedule is not yet known.MethodsWe conducted a systematic literature search in four electronic databases for data published between January 2000 and July 2019 to assess evidence for one-dose and two-dose UV of children with non-live HAV vaccines and describe their global impact on incidence, mortality, and severity of hepatitis A, vaccine effectiveness, vaccine efficacy, and antibody persistence.ResultsOf 3739 records screened, 33 peer-reviewed articles and one conference abstract were included. Rapid declines in incidence of hepatitis A and related outcomes were observed in all age groups post-introduction of UV programs, which persisted for at least 14 years for two-dose and six years for one-dose programs according to respective study durations. Vaccine effectiveness was ≥95% over 3–5 years for two-dose programs. Vaccine efficacy was >98% over 0.1–7.5 years for one-dose vaccination. Antibody persistence in vaccinated individuals was documented for up to 15 years (≥90%) and ten years (≥74%) for two-dose and one-dose schedules, respectively.ConclusionExperience with two-dose UV of children against HAV is extensive, demonstrating an impact on the incidence of hepatitis A and antibody persistence for at least 15 years in many countries globally. Because evidence is more limited for one-dose UV, we were unable to draw conclusions on immune response persistence beyond ten years or the need for booster doses later in life. Ongoing epidemiological monitoring is essential in countries implementing one-dose UV against HAV. Based on current evidence, two doses of non-live HAV vaccines are needed to ensure long-term protection. 相似文献
63.
64.
65.
Association between low‐dose aspirin and periodontal disease: results from the continuous national health and nutrition examination survey (NHANES) 2011–2012
下载免费PDF全文
![点击此处可从《Journal of clinical periodontology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
66.
《Journal of pharmaceutical sciences》2019,108(7):2207-2237
This review describes the landscape of novel modalities such as cell and gene therapies, viruses, other novel biologics, oligomers, and emerging technologies, including modern analytics. We summarize the regulatory history and recent landmark developments in some major markets and examine specific chemistry, manufacturing, and controls (CMC) challenges, including suggestions for exploration of potential science-based approaches in support of regulatory strategy development from an industry perspective. In addition, we evaluate the economic factors contributing to patient access to innovation and discuss the impact of regulation. There is a desperate need for a consistent form of regulation where global approaches to regulatory strategies can be harmonized, and specific CMC challenges can be dealt with using the appropriate science and risk-based tools. Although these tools are well described in current guidance documents, the specifics of applicability to complex novel modalities can still result in differing regulatory advice and outcomes. The future goals for efficiently regulating innovative modalities and technologies could be aided by more regulatory harmonization, regulatory education, and industry cooperation through consortia, enabling industry to supply key information to regulators in a transparent yet well-defined manner, and utilizing mutually understood risk-benefit analyses to produce drugs with appropriate safety, efficacy, and quality characteristics. 相似文献
67.
68.
Cuiqing Fan Chuntao Zhao Feng Zhang Meenu Kesarwani Zhaowei Tu Xiongwei Cai Ashley Kuenzi Davis Lingli Xu Cindy L. Hochstetler Xiaoyi Chen Fukun Guo Gang Huang Mohammad Azam Weidong Tian Q. Richard Lu Yi Zheng 《Proceedings of the National Academy of Sciences of the United States of America》2021,118(1)
69.
ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine‐induced thrombotic microangiopathy
下载免费PDF全文
![点击此处可从《Journal of clinical apheresis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Peter G. Bittar Myles S. Nickolich Oluwatoyosi A. Onwuemene 《Journal of clinical apheresis》2018,33(3):423-426
In the implementation of American Society for Apheresis national guidelines, the decision for therapeutic plasma exchange may be confounded by a clinical presentation that fits both a Category I and IV designation. We report the case of a 45‐year‐old female who presented with concern for a Category IV disorder, gemcitabine‐induced thrombotic microangiopathy, and was ultimately diagnosed with a Category I disorder, idiopathic thrombotic thrombocytopenic purpura. This case highlights the importance of ruling out idiopathic TTP by a thorough evaluation for ADAMTS13 activity and inhibitor, even when an alternate thrombotic microangiopathy diagnosis may be likely. 相似文献
70.